Tekla Capital Management LLC Protagonist Therapeutics, Inc Transaction History

Tekla Capital Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$7.36 - $11.17 $899,914 - $1.37 Million	122,271 New	122,271 $1.33 Million
Q1 2022 May 13, 2022	BUY	$23.34 - $36.08 $495,601 - $766,122	21,234 Added 21.02%	122,271 $2.9 Million
Q4 2021 Feb 14, 2022	BUY	$17.63 - $37.1 $260,923 - $549,080	14,800 Added 17.16%	101,037 $3.46 Million
Q3 2021 Nov 12, 2021	BUY	$12.95 - $49.69 $1.12 Million - $4.29 Million	86,237 New	86,237 $1.53 Million
Q3 2019 Nov 13, 2019	SELL	$9.41 - $16.56 $1.14 Million - $2.01 Million	-121,341 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$8.98 - $12.96 $503,634 - $726,848	-56,084 Reduced 31.61%	121,341 $1.47 Million
Q1 2019 May 14, 2019	SELL	$6.5 - $13.77 $128,134 - $271,448	-19,713 Reduced 10.0%	177,425 $2.23 Million
Q4 2018 Feb 13, 2019	SELL	$6.3 - $10.44 $137,995 - $228,677	-21,904 Reduced 10.0%	197,138 $1.33 Million
Q1 2018 May 14, 2018	BUY	$8.46 - $23.08 $1.15 Million - $3.14 Million	136,220 Added 164.47%	219,042 $1.88 Million
Q4 2017 Feb 14, 2018	BUY	$14.47 - $20.8 $1.09 Million - $1.56 Million	75,000 Added 958.83%	82,822 $1.72 Million
Q3 2017 Nov 13, 2017	BUY	$10.61 - $17.98 $82,991 - $140,639	7,822	7,822 $138,000

247

56.4M

76.3K

114K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Tekla Capital Management LLC with notifications on news.